Travere Therapeutics Inc’s filing revealed that its CHIEF FINANCIAL OFFICER Cline Christopher R. unloaded Company’s shares for reported $631.0 on Apr 11 ’25. In the deal valued at $13.14 per share,48 shares were sold. As a result of this transaction, Cline Christopher R. now holds 89,990 shares worth roughly $1.34 million.
Then, Christopher Cline bought 48 shares, generating $631 in total proceeds.
Before that, ROTE WILLIAM E. sold 5,200 shares. Travere Therapeutics Inc shares valued at $122,356 were divested by the SENIOR VICE PRESIDENT, R&D at a price of $23.53 per share. As a result of the transaction, ROTE WILLIAM E. now holds 98,519 shares, worth roughly $1.47 million.
Cantor Fitzgerald initiated its Travere Therapeutics Inc [TVTX] rating to an Overweight in a research note published recently. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who increased its forecast for the stock in late October from “an Equal weight” to “an Overweight”. Scotiabank began covering TVTX with “Sector outperform” recommendation on October 16, 2024. Guggenheim revised its rating on September 09, 2024. It rated TVTX as “a Buy” which previously was an “a Neutral”.
Price Performance Review of TVTX
On Thursday, Travere Therapeutics Inc [NASDAQ:TVTX] saw its stock jump 2.40% to $14.92. Over the last five days, the stock has gained 10.60%. Travere Therapeutics Inc shares have fallen nearly -14.35% since the year began. Nevertheless, the stocks have risen 142.60% over the past one year. While a 52-week high of $25.29 was reached on 02/11/25, a 52-week low of $5.12 was recorded on 04/09/25. SMA at 50 days reached $19.33, while 200 days put it at $16.03.
Levels Of Support And Resistance For TVTX Stock
The 24-hour chart illustrates a support level at 14.65, which if violated will result in even more drops to 14.39. On the upside, there is a resistance level at 15.09. A further resistance level may holdings at 15.27. The Relative Strength Index (RSI) on the 14-day chart is 37.08, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.61, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 68.30%. Stochastics %K at 25.94% indicates the stock is a holding.
How much short interest is there in Travere Therapeutics Inc?
A steep rise in short interest was recorded in Travere Therapeutics Inc stocks on 2025-03-31, growing by 0.61 million shares to a total of 11.56 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 10.95 million shares. There was a rise of 5.26%, which implies that there is a positive sentiment for the stock.
